Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case

United Therapeutics’ denials of and restrictions on 340B pricing involving contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge.

Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C.

The groups—American Hospital

Read More »

House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings

HHS Secretary Xavier Becerra's plan to fight excessive drug prices will be published publicly in the coming weeks, a White House official said yesterday.

As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue.  While the proposals are going to be

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

The California-based company posted a notice about the availability of the refunds last week on

Read More »

N.C. Lawmakers Debate Over the Reach of 340B “Pickpocketing” Protections

North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.

North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.

Last week Thursday, state House and Senate leaders appointed members to a conference committee

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Jim Donnelly, President, Hudson Headwaters 340B

Jim Donnelly

Q: Where did you grow up?

Glens Falls NY in the foothills of the Adirondack Mountains

Q: Where did you go to college/graduate school?

SUNY Adirondack and Union College

Q: What are your favorites?

Food: Lobster and clams by the ocean in Maine

Movie: One Flew Over the Cuckoo’s Nest

Musicians: Eric Clapton,

Read More »

340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates. A whistleblower is pursuing a similar case against Lilly.

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.

Read More »

PhRMA Challenges First State Law Protecting 340B Contract Pharmacy Program

In 2023, Arkansas became the first state to move to enforce a 340B contract pharmacy law as manufacturer restrictions continued to increase.

Arkansas has temporarily suspended enforcement of the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by contract pharmacies.

State Insurance Commissioner Alan McClain ordered the 90-day suspension on July

Read More »

Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy

Drug manufacturer Merck is defending and hospital groups are condemning the drug company's decision to impose mandatory conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.

Groups that represent hospitals in the drug discount program say Merck

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live